Why the study?
Following the addition of unsupervised home-based training and a 4-week refresher period to Austrian phase III outpatient cardiac rehabilitation, the study aimed to assess the effectiveness of this programme using a nationwide registry.
Does the Austrian phase III cardiac rehabilitation model improve exercise capacity, lipid profiles, and psychological well-being in cardiac patients?
Does the Austrian phase III cardiac rehabilitation model improve exercise capacity, lipid profiles, and psychological well-being in cardiac patients?
The Austrian phase III cardiac rehabilitation model, which incorporates a novel refresher period after home-based training, is associated with sustained improvements in exercise capacity, lipid profiles, and psychological well-being.
Sustained gains in exercise capacity and lipids after Austrian OUT-III CR support extended models; leaves open effects on clinical events.
Introduction The Austrian model of outpatient cardiac rehabilitation (CR) begins right after discharge from the acute care hospital. During phase II (OUT-II), it provides a facility-based, professionally supervised, multidisciplinary programme of 6 weeks. The subsequent, supervised phase III (OUT-III) lasts 6 months. In 2017, a 3–6 months lasting unsupervised home-based training has been added, which is followed by a 4-week facility-based evaluation and training period, called ‘refresher’. We aimed to assess the effectiveness of this programme using a nationwide registry. Methods Anthropometric data, resting blood pressure, lipid profile, maximum exercise capacity (P max ), anxiety (HADS-A) and depression (HADS-D) of all patients (n=1458) who participated in OUT-III between 1 January 2018 and 30 August 2022 were analysed. Data were assessed at the beginning of OUT-III (OUT-III start ), end of the supervised period (OUT-III end ) and during the refresher (OUT-III refresher ). Results From OUT-III start to OUT-III end , P max (155±1.4 W to 167±1.6 W; p<0.001) and high-density lipoprotein (HDL) increased (49±0.4 mg/dL to 51±0.4 mg/dL; p<0.001), low-density lipoprotein (LDL) decreased (82±1.0 mg/dL to 79±1.1 mg/dL; p<0.001), while total cholesterol (CHOL) remained statistically unchanged (150±43.3 mg/dL to 149±43 mg/dL; p<0.999). From OUT-III end to OUT-III refresher , P max slightly decreased (164±1.6 W; p<0.001), HDL further increased (52±0.5 mg/dL; p<0.020), whereas LDL (79±1.3 mg/dL; p<0.999) and CHOL remained unchanged (149±41 mg/dL; p < 0.999). Anxiety (4.8±0.1 aU, 4.2±0.1 aU; p<0.001, 4.0±0.1 aU; p<0.001) and depression (3.7±0.1 aU, 34±0.1 aU; p<.001, 3.1±0.1 aU; p<0.001) continuously decreased from OUT-III start to OUT-III end and the OUT-III refresher . Conclusion OUT-III CR resulted in sustained improvement in P max , blood lipids, anxiety and depression.
No takes yet. Share an insight, caveat, or question.
Reich et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: